Genscript Biotech (HKSE:01548) Debt-to-EBITDA : -3.95 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genscript Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$514 Mil. Genscript Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,742 Mil. Genscript Biotech's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-824 Mil. Genscript Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -3.95.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genscript Biotech's Debt-to-EBITDA or its related term are showing as below:

HKSE:01548' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67 Med: -0.3 Max: 0.29
Current: -1.67

During the past 10 years, the highest Debt-to-EBITDA Ratio of Genscript Biotech was 0.29. The lowest was -1.67. And the median was -0.30.

HKSE:01548's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs HKSE:01548: -1.67

Genscript Biotech Debt-to-EBITDA Historical Data

The historical data trend for Genscript Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Debt-to-EBITDA Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.26

-0.22

-0.34

-0.99

-1.67

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial														-0.23	-0.58	-1.11	-0.97	-3.95

Competitive Comparison of Genscript Biotech's Debt-to-EBITDA

For the Biotechnology subindustry, Genscript Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Debt-to-EBITDA falls into.

Genscript Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genscript Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(514.494	+	2742.114)	/	-1947.944
	=	-1.67

Genscript Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(514.494	+	2742.114)	/	-824.012
	=	-3.95

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Genscript Biotech (HKSE:01548) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Genscript Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (HKSE:01548) Headlines

No Headlines